Cite
Taromi S, Lewens F, Arsenic R, et al. Proteasome inhibitor bortezomib enhances the effect of standard chemotherapy in small cell lung cancer. Oncotarget. 2017;8(57):97061-97078doi: 10.18632/oncotarget.21221.
Taromi, S., Lewens, F., Arsenic, R., Sedding, D., Sänger, J., Kunze, A., Möbs, M., Benecke, J., Freitag, H., Christen, F., Kaemmerer, D., Lupp, A., Heilmann, M., Lammert, H., Schneider, C. P., Richter, K., Hummel, M., Siegmund, B., Burger, M., Briest, F., & Grabowski, P. (2017). Proteasome inhibitor bortezomib enhances the effect of standard chemotherapy in small cell lung cancer. Oncotarget, 8(57), 97061-97078. https://doi.org/10.18632/oncotarget.21221
Taromi, Sanaz, et al. "Proteasome inhibitor bortezomib enhances the effect of standard chemotherapy in small cell lung cancer." Oncotarget vol. 8,57 (2017): 97061-97078. doi: https://doi.org/10.18632/oncotarget.21221
Taromi S, Lewens F, Arsenic R, Sedding D, Sänger J, Kunze A, Möbs M, Benecke J, Freitag H, Christen F, Kaemmerer D, Lupp A, Heilmann M, Lammert H, Schneider CP, Richter K, Hummel M, Siegmund B, Burger M, Briest F, Grabowski P. Proteasome inhibitor bortezomib enhances the effect of standard chemotherapy in small cell lung cancer. Oncotarget. 2017 Sep 23;8(57):97061-97078. doi: 10.18632/oncotarget.21221. eCollection 2017 Nov 14. PMID: 29228593; PMCID: PMC5722545.
Copy
Download .nbib